Original Article
Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia
N Engl J Med 2003; 349:743-752August 21, 2003
- Abstract
Background
Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML).
Methods
In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on disease-free survival was assessed in all patients and in cytogenetically distinct prognostic subgroups.
Results
After induction chemotherapy, the rates of response were not significantly different in the two groups. After a median follow-up of 55 months, patients in complete remission after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02), owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF therapy (overall survival at four years, 45 percent, as compared with 35 percent in the group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence interval, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk, 0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006).
Conclusions
Sensitization of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML.
Media in This Article
Figure 1
Treatment Regimens.Figure 2
Cumulative Rate of Overall Survival (Panel A) and Disease-free Survival (Panel B), According to the Assigned Treatment.Article Activity
- Article
Prevention of relapse remains a challenge in the treatment of acute myeloid leukemia (AML).1 The high rate of recurrence is due to the reemergence of leukemia from small numbers of residual cells that have escaped the cytotoxic effect of chemotherapy.
Hematopoietic growth factors stimulate AML cells in culture, activating metabolic processes and the cell cycle. In vitro, the simultaneous exposure of leukemic cells to chemotherapy and growth factors such as granulocyte–macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and interleukin-3, referred to as growth-factor priming, increases the susceptibility of the cells to killing by chemotherapy, especially by the cell-cycle–specific agent cytarabine.2-11 These observations suggest a novel therapeutic strategy for AML, but the value of such an approach has not been assessed clinically.
In previous trials of AML, G-CSF and GM-CSF have been widely used after chemotherapy to accelerate myeloid regeneration,12-14 but there is information only from uncontrolled studies15-17 and small, randomized studies18-21 about their use in growth-factor priming. We conducted a randomized trial to determine whether G-CSF given only during the first two induction cycles with cytarabine plus idarubicin and cytarabine plus amsacrin improves disease-free survival in adults with newly diagnosed AML by increasing the rate of complete response, reducing the relapse rate, or both. G-CSF was not given during the aplastic phase after chemotherapy. To avoid interference of the second chemotherapeutic agent with the cell-cycle–dependent synergy between cytarabine and G-CSF, idarubicin (first cycle) and amsacrin (second cycle) were given at the end of the cycles.
Methods
Patients
Previously untreated patients with a confirmed diagnosis of AML who were 18 to 60 years of age were eligible for the study. All subtypes of AML were included, except acute promyelocytic leukemia and blast crisis of chronic myeloid leukemia. Patients with another active cancer were not eligible, nor were patients with severe heart, lung, or neurologic disease. All patients were screened for eligibility before undergoing randomization.
The study was approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. All participants gave their informed consent.
Risk Classification
At diagnosis, samples of bone marrow and blood were examined for cytogenetic abnormalities with the use of standard banding techniques and classified according to the International System for Human Cytogenetic Nomenclature.22 On the basis of the chromosomal analysis, patients were classified into three distinct prognostic categories: favorable risk, unfavorable risk, and standard risk.23-25 Favorable risk was defined by the presence of t(8;21)(q22;22), inv16(p13q22), or t(16;16)(p13q22) and a white-cell count of less than 20×103 per cubic millimeter at diagnosis.25 Unfavorable risk was defined by the presence of complex cytogenetic abnormalities (defined as at least four unrelated cytogenetic clones), monosomies, or deletions of chromosome 5 or 7 (5q–, 7q–, –5, or –7), abnormalities of the long arm of chromosome 3(q21;q26), t(6;9)(p23;q34), or abnormalities involving the long arm of chromosome 11(11q23). Leukemias that had occurred after chemotherapy or radiotherapy for a nonhematologic condition and leukemias that had occurred more than six months after a hematologic condition (secondary leukemias) were included in the unfavorable prognostic category. Patients who did not meet the criteria for favorable or unfavorable risk were classified as being at standard risk.
Study Design and Chemotherapy
Patients were enrolled and randomly assigned to receive G-CSF or no G-CSF during remission-induction cycles 1 and 2 (Figure 1Figure 1
Treatment Regimens.). Cycle 1 consisted of cytarabine (200 mg per square meter of body-surface area given by continuous infusion on days 1 through 7) and idarubicin (12 mg per square meter given intravenously over a period of 5 to 10 minutes on days 6, 7, and 8). Cycle 2 consisted of cytarabine (1000 mg per square meter given intravenously over a period of 2 hours every 12 hours on days 1 through 6) and amsacrin (120 mg per square meter given intravenously over a 60-minute period on days 4, 5, and 6). G-CSF (lenograstim, Aventis) was given subcutaneously or intravenously in a dose of 150 μg per square meter per day beginning one day before chemotherapy (day 0) and continuing until the last day of cycles 1 and 2. The administration of G-CSF was postponed or interrupted in the event of leukocytosis (more than 30×103 leukocytes per cubic millimeter) until the white-cell count was below 20×103 per cubic millimeter. Patients with standard-risk or unfavorable-risk AML who were in complete remission after cycle 2 were randomly assigned to a third cycle of chemotherapy with etoposide and mitoxantrone or high-dose chemotherapy with busulfan and cyclophosphamide followed by autologous stem-cell transplantation. Allogeneic stem-cell transplantation was performed if a suitable donor was available and the patient was younger than 55 years of age. Patients with a favorable cytogenetic profile were also to receive the third cycle of chemotherapy with etoposide and mitoxantrone.Statistical Analysis
The primary objective of the study was to determine the effect of adding G-CSF to induction chemotherapy on the rate of response, disease-free survival, relapse-free survival, and overall survival. A secondary objective was to assess the relation between the defined prognostic subgroups and the outcome. A complete response was defined by cellular marrow with less than 5 percent blasts, no Auer rods, no evidence of extramedullary leukemia, and peripheral granulocyte and platelet counts of at least 1.0×103 per cubic millimeter and 100×103 per cubic millimeter, respectively. The time to hematopoietic recovery after both cycles 1 and 2 was measured from the first day of chemotherapy. Disease-free survival was measured from the time of the first complete remission to the date of relapse or death from any cause. Relapse was defined as a recurrence of leukemia after a first complete remission. Event-free survival was measured from the date of randomization to the date of failure to enter a complete remission (set as day 1), death, or relapse, whichever came first. Overall survival was measured from the date of randomization.
Random assignments were balanced with use of a minimization procedure with the hospital as a stratification factor. We planned to enroll 600 patients over a period of five years, with an additional follow-up of two years after the enrollment of the last patient. This number of patients would give the study a power of 78 percent to show an absolute increase of 10 percent in the rate of complete remission (from 70 percent to 80 percent) with the use of G-CSF; a power of 75 percent to show an absolute increase of 10 percent in the overall survival rate (from 35 percent to 45 percent) at three years, given a relative risk of death of 0.76 and with 375 expected deaths; and a power of 81 percent to show an absolute increase of 10 percent in long-term event-free survival (from 25 percent to 35 percent) at three years, given a relative risk of 0.76 and 423 expected events, with the use of two-sided tests and a 5 percent significance level. Within 3.5 years, 655 patients had been recruited, 640 of whom could be evaluated. As of August 2002, 445 events had occurred, as defined with respect to event-free survival, and 407 patients had died.
All analyses were conducted according to the intention-to-treat principle, but 14 ineligible patients (7 in each group) were excluded, as was 1 who was lost to follow-up on day 3 and whose data could therefore not be evaluated. Reasons for ineligibility were an incorrect diagnosis (lymphoid neoplasia) in eight patients and myelodysplasia in six. Logistic regression was used to analyze the effect of G-CSF on the rate of complete remission, whereas the log-rank test and Cox regression analysis were used to analyze the differences between the two groups with respect to overall survival, event-free survival, and disease-free survival. These analyses were done before and after adjustment for age, risk category, and transplantation status during a first complete remission (as a time-dependent covariate). Competing risk analysis was used to calculate the cumulative competing risks of treatment failure among patients with a complete response (defined as relapse after a complete remission and death during a first complete remission).
The rates of hematologic recovery after cycles 1 and 2 were analyzed actuarially and compared with the use of the log-rank test. In these analyses, data on patients were censored at death or at the start of the next treatment, if hematologic recovery had not yet occurred. All P values reported are two-tailed.
Results
Characteristics of the Patients and Adherence to G-CSF Treatment
Between March 1995 and January 1999, 319 patients were assigned to induction chemotherapy without G-CSF, and 321 patients were assigned to chemotherapy combined with G-CSF. As of the time of the data analysis, the median follow-up was 55 months, and 90 percent of the patients had been followed for more than 40 months. Thirteen patients were lost to follow-up or were last seen more than one year before the analysis. Of these 13 patients, 7 had been followed for more than three years.
The two treatment groups were evenly matched with respect to various factors, including assignment to postinduction therapy (Table 1Table 1
Characteristics of the Patients with Acute Myeloid Leukemia (AML).). As for the prognostic risk groups, most patients were in the standard-risk category, and approximately 20 percent were in the unfavorable-risk category (Table 1). Only about 7 percent of all the patients presented with prognostically favorable AML.In cycle 1, G-CSF was not given to 16 of the 321 patients who were assigned to receive G-CSF; treatment with G-CSF was delayed (median period, four days) in 120 of the patients and interrupted (median period, two days) in 30 patients. The primary reason for these deviations was leukocytosis (in 75 percent of cases), as prespecified in the protocol. Other reasons, based on decisions by local physicians, were usually related to medical problems (e.g., infections, hemorrhage, liver-function abnormalities, and urticaria). Of the 279 patients in the G-CSF group who proceeded to cycle 2, G-CSF was not given to 23 patients because of leukocytosis, persistent leukemia, or deviations from the protocol, including 1 patient because of chemotherapy-associated toxicity during cycle 1. In 19 patients treatment with G-CSF was postponed (median period, one day) because of leukocytosis or deviations from the protocol.
Response and Adverse Effects
The rates of complete remission were 83 percent in the group that did not receive G-CSF and 79 percent in the group that received G-CSF (P=0.24) (Table 2Table 2
Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcome of Acute Myeloid Leukemia (AML) at Four Years.). In both groups, 73 percent of the complete remissions occurred after cycle 1. The rates of complete remission in the two groups did not differ significantly according to age or risk group. The frequencies of various grade 3 (severe) or grade 4 (very severe) adverse effects (according to World Health Organization criteria) after cycles 1 and 2 and the times to hematopoietic recovery after cycles 1 and 2 were similar in the two groups (Table 3Table 3
Incidence of Grade 3 or 4 Side Effects and Hematopoietic Recovery after Induction-Therapy Cycles 1 and 2.). There were more deaths within 50 days after cycles 1 and 2 among patients who received G-CSF than among patients who did not receive G-CSF (Table 4Table 4
Mortality Rates Associated with Induction Chemotherapy with Granulocyte Colony-Stimulating Factor (G-CSF) and without G-CSF.).Relapse and Survival
Among patients who had a complete remission, the disease-free survival rate at four years was higher in the G-CSF group than in the group that did not receive G-CSF (42 percent vs. 33 percent; relative risk of relapse or death, 0.77; 95 percent confidence interval, 0.62 to 0.96; P=0.02) (Table 2 and Figure 2Figure 2
Cumulative Rate of Overall Survival (Panel A) and Disease-free Survival (Panel B), According to the Assigned Treatment.). This difference was related to a lower relapse rate in the G-CSF group (46 percent vs. 54 percent; relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04) (Table 2). At four years there were no statistically significant differences between the two groups in the rates of overall and event-free survival (Table 2 and Figure 2). The unadjusted Cox regression analysis and an analysis adjusted for age, risk category, and presence or absence of subsequent stem-cell transplantation during a first complete remission (time-dependent covariates) yielded similar estimates for the hazard rates associated with treatment results and P values (data not shown).Outcome among Distinct Prognostic Subgroups
Among patients with standard-risk AML (72 percent of all patients), treatment with G-CSF reduced the probability of relapse and improved overall, event-free, and disease-free survival (Figure 3AFigure 3
Cumulative Rates of Overall Survival (Panels A and C) and Disease-free Survival (Panels B and D) among Patients with Standard-Risk Acute Myeloid Leukemia (AML) and Unfavorable-Risk AML. and Figure 3B and Table 2). G-CSF did not, however, significantly affect overall, event-free, or disease-free survival among the 135 patients with unfavorable-risk AML (Figure 3C and Figure 3D and Table 2). In the 41 patients with favorable-risk AML, G-CSF priming had no effect.Discussion
Incubation of AML cells with G-CSF, GM-CSF, or interleukin-3 and the cell-cycle–dependent agent cytarabine increases intracellular levels of the active metabolite cytosine arabinoside triphosphate, incorporation of cytarabine into cellular DNA,5,7 and the killing of leukemic blasts and leukemic progenitor cells by the drug.2-11 We evaluated the clinical efficacy of growth-factor priming in patients with previously untreated AML. G-CSF was given beginning one day before the start of chemotherapy of cycles 1 and 2 and continued through the last day of induction cycles 1 and 2. Among patients who received G-CSF and who had a complete remission, the relapse rate was lower than that among patients in complete remission who did not receive G-CSF. Moreover, in the group of patients who had a complete remission, the disease-free survival rate at four years was 42 percent in the G-CSF group and 33 percent in the group that did not receive G-CSF (P=0.02). The difference in overall and event-free survival did not reach statistical significance. The significant difference in disease-free survival probably resulted from G-CSF–mediated activation of subpopulations of leukemic cells that were initially insensitive to cytosine arabinoside. Elimination of the primed cells may have reduced the frequency of relapse.
The ability of colony-stimulating factors to activate AML cells has been directly demonstrated in vivo: injection of G-CSF or GM-CSF 18 to 72 hours before the beginning of chemotherapy drives AML cells into the cell cycle.26,27 This effect is consistent with the notion that G-CSF receptors, because of their high binding affinity, require minimal levels of ligands for activation.28
From our data, we cannot determine whether the sensitization effect was mediated by increasing the efficacy of cytarabine, idarubicin and amsacrin, or the combined chemotherapeutic agents we used. In any case, the efficacy of a chemotherapy regimen that included cytarabine at doses of 200 mg per square meter as well as 1000 mg per square meter was enhanced by the addition of G-CSF priming. Studies of the dose effect of cytarabine have shown that doses of 3 g per square meter29,30 were more effective than doses of 200 or 400 mg per square meter in preventing relapse but did not result in an increased rate of remission. Similarly, in this study, only the duration of remission, not the number of remissions, changed as the result of G-CSF sensitization.
We used a dose of 1 g of cytarabine per square meter in cycle 2. The comparative effect of a dose of 1 g per square meter and a dose of 3 g per square meter has not been established in AML therapy. It would be of interest to know whether G-CSF priming would have a similarly positive effect on the probability of relapse in regimens containing a dose of 3 g of cytarabine per square meter.
The fact that our results do not suggest a benefit of G-CSF priming in patients with favorable-risk AML might relate to the small numbers of cases, or it might indicate that the dose of 1 g of cytarabine per square meter was optimal in terms of its ability to kill neoplastic cells in this subgroup. After the two induction cycles with or without G-CSF, approximately one third of patients received a third cycle of chemotherapy and another third went on to high-dose chemotherapy followed by stem-cell transplantation. It is unlikely that the postinduction treatment influenced the outcome of G-CSF treatment. The two groups were evenly matched in terms of assignment to postinduction therapy. Besides, Cox regression analysis with autologous and allogeneic transplantation during a first remission as time-dependent covariates yielded results similar to those of the unadjusted analysis.
The fact that more deaths occurred during induction among patients who received G-CSF may explain the slightly reduced rate of complete remission in this group. These deaths had several causes and were thus not due to a common problem. However, because of a reduction in the incidence of later deaths, the overall death rate among patients in the G-CSF group was lower than that among those treated with chemotherapy alone.
Previous studies of G-CSF and GM-CSF in AML have been almost entirely confined to the ability of these growth factors to accelerate hematopoietic recovery and reduce morbidity and mortality due to infection after chemotherapy. The efficacy of these agents in modulating chemotherapy has, however, been evaluated in controlled18-21 and uncontrolled15-17 studies involving limited numbers of patients. In two relatively large, randomized studies, GM-CSF was administered concomitantly with and after chemotherapy.31,32 These studies involved older patients, most of whom had AML with an unfavorable prognosis. One of these studies reported a higher rate of disease-free survival among the patients who received GM-CSF than among those who did not receive GM-CSF,32 but it was not possible to distinguish the effect of priming from the effect of enhanced hematopoietic recovery. By contrast, our study selectively focused on the effect of growth-factor priming in AML and was conducted in young and middle-aged adults with previously untreated leukemia.
We found that G-CSF improved overall and disease-free survival in the group with standard-risk AML. There were too few patients in the group with a favorable prognosis to allow a meaningful analysis. There was no indication that G-CSF priming improved the outcome among patients with chemotherapy-refractory, unfavorable-risk AML. This lack of benefit explains why overall survival was not significantly better in the G-CSF group as a whole.
Additional studies of G-CSF priming in specific subgroups of patients and regimens of combination therapy seem warranted. The results of our study provide proof of the principle that chemotherapy and sensitization of leukemia cells by hematopoietic growth factors is a plausible strategy for reducing the risk of relapse in patients with AML.
Local data management was supported by the Dutch Cancer Society Queen Wilhelmina Fund. Aventis provided an unrestricted grant for central data management to the Dutch–Belgian Hemato-Oncology (HOVON) Cooperative Group and provided lenograstim free of charge.
We are indebted to Janine Vrij for secretarial assistance.
Source Information
From the Department of Hematology (B.L., P.S., G.G.) and the HOVON Data Center and Department of Statistics (W.P.), Erasmus University Medical Center, Rotterdam, the Netherlands; the Department of Hematology and Oncology, Johannes Gutenberg–University Hospital, Mainz, Germany (M.T.); Onkozentrum, Hirslanden Klinik Im Park, Zurich, Switzerland (J.G.); the Department of Hematology, University Medical Center, Utrecht, the Netherlands (L.V.); the Institute of Medical Oncology, University and Inselspital, Berne, Switzerland (M.F.); the Department of Internal Oncology and Hematology, University Hospital, Maastricht, the Netherlands (H.S.); the Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium (A.F.); the Division of Hematology, University Hospital, Lausanne, Switzerland (T.K.); the Division of Hematology, Kantonsspital, Basel, Switzerland (A.G.); the Department of Hematology, University Hospital, Groningen, the Netherlands (S.D.); the Department of Hematology, Free University Medical Center, Amsterdam (P.H.); and the Department of Hematology, Hospital Gasthuisberg, Leuven, Belgium (M.B.).
Address reprint requests to Dr. Löwenberg at Erasmus University Medical Center, Department of Hematology, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands, or at b.lowenberg@erasmusmc.nl.
Appendix
The following centers and persons participated in the study: Study coordinators — B. Löwenberg, M.A. Boogaerts, and J. Gmür; Statistician — W. van Putten (Dutch–Belgian Hemato-Oncology [HOVON] Cooperative Group Data Center, Rotterdam, the Netherlands); Cytogenetic review — A. Hagemeijer (Leuven, Belgium), S.L. Bhola (Leiden, the Netherlands), and M. Jotterand-Bellomo (Lausanne, Switzerland); Cytology review committee — M.B. van 't Veer (Rotterdam, the Netherlands), J. Fehr (Zurich, Switzerland); Central data management — A.J.M. Meurisse, M. van Os (HOVON Cooperative Group Data Center) and B. Rufener (Swiss Group for Clinical Cancer Research Trial Office Center, Bern, Switzerland); Participating centers (and investigators) — the Netherlands: Free University Medical Center, Amsterdam (P.C. Huijgens, G.J. Ossenkoppele); University Hospital, Groningen (S.M.J.G. Daenen, E. Vellenga); University Hospital, Utrecht (A.W. Dekker, L.F. Verdonck); Erasmus Medical Center and Daniel den Hoed Cancer Center, Rotterdam (B. Löwenberg, P. Sonneveld, G.E. de Greef); University Hospital, Maastricht (H.C. Schouten); University Hospital, Amsterdam (J. van der Lelie); Leijenburg Hospital, The Hague (P.W. Wijermans); Hospital Eemland, Amersfoort (S. Wittebol); Medical Center Twente, Enschede (M.R. Schaafsma); Sophia Hospital, Zwolle (M. van Marwijk Kooy); Antonius Hospital, Nieuwegein (D.H. Biesma); Antoni van Leeuwenhoekhuis, Amsterdam (J.W. Baars); Diaconessen Hospital, Meppel (H. de Korte); Hospital Reinier de Graaf, Delft (E. Maartense); Medical Center, Leeuwarden (P. Joosten); Catharina Hospital, Eindhoven (W.G. Peters); and Hospital Gooi Noord, Blaricum (H.P. Muller); Belgium: Hospital Gasthuisberg, Leuven (M.A. Boogaerts, G. Verhoef); Cliniques Universitaires Saint-Luc, Brussels (A. Ferrant); Cliniques Universitaires de Mont-Godinne, Yvoir (A. Bosly); and Hôpital de Jolimont, Haine-St. Paul (A. Delannoy); Germany: Johannes Gutenberg-University Hospital, Mainz (M. Theobald, J. Beck); and Nordwest Hospital, Frankfurt am Main (A. Knuth); Switzerland: University Hospital, Zurich (J. Gmür, E. Jacky); University Hospital, Bern (M.F. Fey, A. Tobler); University Hospital, Lausanne (T. Kovacsovics); University Hospital, Basel (A. Gratwohl, A. Tichelli); Kantonsspital, St. Gallen (U. Hess); Hôpital Cantonal Universitaire, Geneva (B. Chapuis); University Hospital, Neuchâtel (D. Piguet); Hospital St. Giovanni, Bellinzona (L. Leoncini); Kantonsspital, Winterthur (T. Kroner); and Kantonsspital, Arau (M. Wernli).
- References
References
1
Lowenberg B ,Downing JR ,Burnett A . Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062[Erratum, N Engl J Med 1999;341:1484.]
Full Text | Web of Science | Medline2
Bhalla K ,Birkhofer M ,Arlin Z ,Grant S ,Lutzky J ,Graham G . Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810-813
Web of Science | Medline3
Lista P ,Porcu P ,Avanzi GC ,Pegoraro L . Interleukin 3 enhances the cytotoxic activity of 1-β-D-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukaemia (AML) cells. Br J Haematol 1988;70:121-123
CrossRef | Web of Science | Medline4
Miyauchi J ,Kelleher CA ,Wang C ,Minkin S ,McCulloch EA . Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272-1278
Web of Science | Medline5
Tanaka M . Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res 1993;17:585-592
CrossRef | Web of Science | Medline6
Cannistra SA ,Groshek P ,Griffin JD . Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989;3:328-334
Web of Science | Medline7
Bhalla K ,Holladay C ,Arlin Z ,Grant S ,Ibrado AM ,Jasiok M . Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 1991;78:2674-2679
Web of Science | Medline8
Te Boekhorst PA ,Lowenberg B ,Sonneveld P . Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480-1486
Web of Science | Medline9
Te Boekhorst PA ,Lowenberg B ,Vlastuin M ,Sonneveld P . Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191-1198
Web of Science | Medline10
Inatomi Y ,Toyama K ,Clark SC ,Shimizu K ,Miyauchi J . Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994;54:455-462
Web of Science | Medline11
Reuter C ,Auf der Landwehr U ,Schleyer U , et al. Modulation of intracellular metabolism in cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 1994;8:217-225
Web of Science | Medline12
Terpstra WE ,Lowenberg B . Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997;11:315-327
CrossRef | Web of Science | Medline13
Schiffer CA . Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675-3685
Web of Science | Medline14
Ohno R . Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Res 1998;22:1143-1154
CrossRef | Web of Science | Medline15
Rossi HA ,O'Donnell J ,Sarcinelli F ,Stewart FM ,Quesenberry PJ ,Becker PS . Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2002;16:310-315
CrossRef | Web of Science | Medline16
Frenette PS ,Desforges JF ,Schenkein DP ,Rabson A ,Slapack CA ,Miller KB . Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol 1995;49:48-55
CrossRef | Web of Science | Medline17
Estey E ,Thall PF ,Kantarjian H , et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79:2246-2255
Web of Science | Medline18
Ohno R ,Naoe T ,Kanamaru A , et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood 1994;83:2086-2092
Web of Science | Medline19
Zittoun R ,Suciu S ,Mandelli F , et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996;14:2150-2159
Web of Science | Medline20
Lowenberg B ,Boogaerts MA ,Daenen SM , et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-3506
Web of Science | Medline21
Estey EH ,Thall PF ,Pierce S , et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93:2478-2484
Web of Science | Medline22
Mitelman F, ed. ICSN 1995: an international system for human cytogenetic nomenclature (1995). Basel, Switzerland: Karger, 1995.
23
Mrozek K ,Heinonen K ,de la Chapelle A ,Bloomfield CD . Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31
Web of Science | Medline24
Wheatley K ,Burnett AK ,Goldstone AH , et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79
CrossRef | Web of Science | Medline25
Lowenberg B . Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:65-75
CrossRef | Web of Science | Medline26
Cannistra SA ,DiCarlo J ,Groshek P , et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991;5:230-238
Web of Science | Medline27
Baer MR ,Bernstein SH ,Brunetto VL , et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996;87:1484-1494
Web of Science | Medline28
Lowenberg B ,Touw IP . Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-292
Web of Science | Medline29
Mayer RJ ,Davis RB ,Schiffer CA , et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903
Full Text | Web of Science | Medline30
Bishop JF ,Matthews JP ,Young GA , et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-1717
Web of Science | Medline31
Lowenberg B ,Suciu S ,Archimbaud E , et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997;90:2952-2961
Web of Science | Medline32
Witz F ,Sadoun A ,Perrin MC , et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998;91:2722-2730
Web of Science | Medline
- Citing Articles (109)
Citing Articles
1
Todd L. Rosenblat, Joseph G. Jurcic. (2011) Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions. Hematology/Oncology Clinics of North America 25:6, 1189-1213
CrossRef2
Eike C. Buss, Anthony D. Ho. (2011) Leukemia stem cells. International Journal of Cancer 129:10, 2328-2336
CrossRef3
Kristin Zeidler, Kornelius Arn, Oliver Senn, Urs Schanz, Georg Stussi. (2011) Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 51:11, 2269-2276
CrossRef4
Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Stephen H. Petersdorf, Barry Storer, Sherry Pierce, Jianqin Shan, Paul C. Hendrie, John M. Pagel, Andrei R. Shustov, Derek L. Stirewalt, Stephan Faderl, Elizabeth Harrington, Elihu H. Estey. (2011) Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. British Journal of Haematology 155:2, 182-189
CrossRef5
Lingyun Wu, Xiao Li, Jiying Su, Qi He, Xi Zhang, Chunkang Chang, Quan Pu. (2011) Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. Journal of Cancer Research and Clinical Oncology 137:10, 1563-1569
CrossRef6
E. Vellenga, W. van Putten, G. J. Ossenkoppele, L. F. Verdonck, M. Theobald, J. J. Cornelissen, P. C. Huijgens, J. Maertens, A. Gratwohl, R. Schaafsma, U. Schanz, C. Graux, H. C. Schouten, A. Ferrant, M. Bargetzi, M. F. Fey, B. Lowenberg. (2011) Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood
CrossRef7
Ronit Gurion, Yulia Belnik-Plitman, Anat Gafter-Gvili, Mical Paul, Liat Vidal, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani, Pia Raanani. 2011. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. .
CrossRef8
N Ånensen, S M Hjelle, W Van Belle, I Haaland, E Silden, J-C Bourdon, R Hovland, K Taskén, S Knappskog, P E Lønning, Ø Bruserud, B T Gjertsen. (2011) Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene
CrossRef9
V. Rockova, S. Abbas, B. J. Wouters, C. A. J. Erpelinck, H. B. Beverloo, R. Delwel, W. L. J. van Putten, B. Lowenberg, P. J. M. Valk. (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118:4, 1069-1076
CrossRef10
Belinda R. Avalos, Aleksandr Lazaryan, Edward A. Copelan. (2011) Can G-CSF Cause Leukemia in Hematopoietic Stem Cell Donors?. Biology of Blood and Marrow Transplantation
CrossRef11
W. A. Wood, S. J. Lee. (2011) Malignant hematologic diseases in adolescents and young adults. Blood 117:22, 5803-5815
CrossRef12
T Kamimura, T Miyamoto, K Nagafuji, A Numata, H Henzan, K Takase, Y Ito, Y Ohno, T Fujisaki, T Eto, Y Takamatsu, T Teshima, H Gondo, K Akashi, S Taniguchi, M Harada. (2011) Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review. Bone Marrow Transplantation 46:6, 820-826
CrossRef13
J. Fos, T. Pabst, V. Petkovic, D. Ratschiller, B. U. Mueller. (2011) Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis. Blood 117:18, 4881-4884
CrossRef14
Ying Wang, Weiyang Li, Suning Chen, Huiying Qiu, Aining Sun, Depei Wu. (2011) Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Leukemia Research 35:5, 604-607
CrossRef15
F. Damm, M. Heuser, M. Morgan, K. Wagner, K. Gorlich, A. Grosshennig, I. Hamwi, F. Thol, E. Surdziel, W. Fiedler, M. Lubbert, L. Kanz, C. Reuter, G. Heil, R. Delwel, B. Lowenberg, P. J. M. Valk, J. Krauter, A. Ganser. (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:17, 4561-4568
CrossRef16
Farhad Ravandi. (2011) New Treatments and Strategies in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia
CrossRef17
Gillian M. Keating. (2011) Lenograstim. Drugs 71:6, 679-707
CrossRef18
Löwenberg, Bob, Pabst, Thomas, Vellenga, Edo, van Putten, Wim, Schouten, Harry C., Graux, Carlos, Ferrant, Augustin, Sonneveld, Pieter, Biemond, Bart J., Gratwohl, Alois, de Greef, Georgine E., Verdonck, Leo F., Schaafsma, Martijn R., Gregor, Michael, Theobald, Matthias, Schanz, Urs, Maertens, Johan, Ossenkoppele, Gert J., . (2011) Cytarabine Dose for Acute Myeloid Leukemia. New England Journal of Medicine 364:11, 1027-1036
Full Text19
Michael Heuser, Antonia Zapf, Michael Morgan, Jürgen Krauter, Arnold Ganser. (2011) Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Annals of Hematology 90:3, 273-281
CrossRef20
Meral Beksac, Ridvan Ali, Tulay Ozcelik, Muhit Ozcan, Osman Ozcebe, Mahmut Bayik, Semra Paydas, Yahya Buyukasik, Osman Ilhan, Fahir Ozkalemkas, Gunhan Gurman, Akin Uysal, Hamdi Akan, Ender Akcaglayan Soydan, Ahmet Tunali. (2011) Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. Leukemia Research 35:3, 340-345
CrossRef21
Kai Hübel, Olaf Weingart, Frauke Naumann, Julia Bohlius, Maximilian M. Fresen, Andreas Engert, Keith Wheatley. (2011) Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leukemia & Lymphoma 52:3, 444-457
CrossRef22
E. Taskesen, L. Bullinger, A. Corbacioglu, M. A. Sanders, C. A. J. Erpelinck, B. J. Wouters, S. C. van der Poel-van de Luytgaarde, F. Damm, J. Krauter, A. Ganser, R. F. Schlenk, B. Lowenberg, R. Delwel, H. Dohner, P. J. M. Valk, K. Dohner. (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:8, 2469-2475
CrossRef23
Yoo Jin Lee, Joon Ho Moon, Jong Gwang Kim, Yee Soo Chae, Byung Woog Kang, Soo Jung Lee, Jun Young Choi, Ho Chul Shin, Jong Won Seo, Sang Kyun Sohn. (2011) Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML. Chonnam Medical Journal 47:2, 80
CrossRef24
H. J. M. de Jonge, P. J. M. Valk, N. J. G. M. Veeger, A. ter Elst, M. L. den Boer, J. Cloos, V. d. Haas, M. M. van den Heuvel-Eibrink, G. J. L. Kaspers, C. M. Zwaan, W. A. Kamps, B. Lowenberg, E. S. J. M. de Bont. (2010) High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116:10, 1747-1754
CrossRef25
Wolfgang Kern, Ulrike Bacher, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach. (2010) The role of multiparameter flow cytometry for disease monitoring in AML. Best Practice & Research Clinical Haematology 23:3, 379-390
CrossRef26
Nelli Bejanyan, Alex Z. Fu, Aleksandr Lazaryan, Rao Fu, Matt Kalaycio, Anjali Advani, Ronald Sobecks, Edward Copelan, Jaroslaw P. Maciejewski, Mikkael A. Sekeres. (2010) Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia. Cancer 116:15, 3614-3620
CrossRef27
Sameer A. Parikh, Tapan Kadia, Elias Jabbour. (2010) Peripheral Blasts on Day 21 of Induction Chemotherapy in a Patient With Core Binding Factor Acute Myeloid Leukemia: More Than Meets the Eye. Clinical Lymphoma, Myeloma & Leukemia 10:4, 301-302
CrossRef28
R. Beekman, I. P. Touw. (2010) G-CSF and its receptor in myeloid malignancy. Blood 115:25, 5131-5136
CrossRef29
M. F. Fey, M. Dreyling, . (2010) Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v158-v161
CrossRef30
Steven W. Lane, D. Gary Gilliland. (2010) Leukemia stem cells. Seminars in Cancer Biology 20:2, 71-76
CrossRef31
Xavier Thomas, Emmanuel Raffoux, Aline Renneville, Cecile Pautas, Stephane de Botton, Christine Terre, Claude Gardin, Sandrine Hayette, Claude Preudhomme, Herve Dombret. (2010) Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 116:7, 1725-1732
CrossRef32
Hanna K A Mikkola, Caius G Radu, Owen N Witte. (2010) Targeting leukemia stem cells. Nature Biotechnology 28:3, 237-238
CrossRef33
Yoriko Saito, Naoyuki Uchida, Satoshi Tanaka, Nahoko Suzuki, Mariko Tomizawa-Murasawa, Akiko Sone, Yuho Najima, Shinsuke Takagi, Yuki Aoki, Atsushi Wake, Shuichi Taniguchi, Leonard D Shultz, Fumihiko Ishikawa. (2010) Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology
CrossRef34
H. Dohner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. Niederwieser, G. J. Ossenkoppele, M. A. Sanz, J. Sierra, M. S. Tallman, B. Lowenberg, C. D. Bloomfield. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:3, 453-474
CrossRef35
Helene Hallböök, Magnus Björkholm, Hans Hägglund, Bengt Smedmyr. (2009) Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia?. Leukemia & Lymphoma 50:11, 1872-1874
CrossRef36
Ron Ram, Pia Raanani. (2009) The role of myeloid colony-stimulating factors in the treatment of acute lymphoblastic leukemia – more questions than answers?. Leukemia & Lymphoma 50:11, 1737-1739
CrossRef37
Mike G. Martin, Kristan M. Augustin, Geoffrey L. Uy, John S. Welch, Lindsay Hladnik, Sagun Goyal, Divya Tiwari, Ryan S. Monahan, Richard M. Reichley, Amanda F. Cashen, Keith Stockerl-Goldstein, Peter Westervelt, Camille N. Abboud, John F. DiPersio, Ravi Vij. (2009) Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. American Journal of Hematology 84:11, 733-737
CrossRef38
H. J. M. de Jonge, E. S. J. M. de Bont, P. J. M. Valk, J. J. Schuringa, M. Kies, C. M. Woolthuis, R. Delwel, N. J. G. M. Veeger, E. Vellenga, B. Lowenberg, G. Huls. (2009) AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 114:14, 2869-2877
CrossRef39
M. J. Christopher, F. Liu, M. J. Hilton, F. Long, D. C. Link. (2009) Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 114:7, 1331-1339
CrossRef40
S. W. Lane, D. T. Scadden, D. G. Gilliland. (2009) The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 114:6, 1150-1157
CrossRef41
M. Heuser, F. Kuchenbauer, B. Argiropoulos, S. Sekulovic, M. Leung, M. Stasiak, A. Ganser, R. K. Humphries. (2009) Priming reloaded?. Blood 114:4, 925-926
CrossRef42
Keith Wheatley, Anthony H. Goldstone, Tim Littlewood, Anne Hunter, Alan K. Burnett. (2009) Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. British Journal of Haematology 146:1, 54-63
CrossRef43
Weidong Lu, Ursula A. Matulonis, Anne Doherty-Gilman, Hang Lee, Elizabeth Dean-Clower, Andrew Rosulek, Carolyn Gibson, Annekathryn Goodman, Roger B. Davis, Julie E. Buring, Peter M. Wayne, David S. Rosenthal, Richard T. Penson. (2009) Acupuncture for Chemotherapy-Induced Neutropenia in Patients with Gynecologic Malignancies: A Pilot Randomized, Sham-Controlled Clinical Trial. The Journal of Alternative and Complementary Medicine 15:7, 745-753
CrossRef44
B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, J. F. DiPersio. (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113:24, 6206-6214
CrossRef45
Andrea Viale, Pier G. Pelicci. (2009) Awaking stem cells from dormancy: growing old and fighting cancer. EMBO Molecular Medicine 1:2, 88-91
CrossRef46
L Sung, S M H Alibhai, J Beyene, A Gamis, R Almeida, S Smith, R Aplenc. (2009) Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. Leukemia 23:4, 811-813
CrossRef47
Eystein Oveland, Bjørn Tore Gjertsen, Line Wergeland, Frode Selheim, Kari E. Fladmark, Randi Hovland. (2009) Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research 33:2, 276-287
CrossRef48
Mehdi Hamadani, Farrukh T. Awan. (2009) Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematological Oncologyn/a-n/a
CrossRef49
Lingyun Wu, Xiao Li, Jiying Su, Chunkang Chang, Qi He, Xi Zhang, Li Xu, Luxi Song, Quan Pu. (2009) Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leukemia & Lymphoma 50:9, 1461-1467
CrossRef50
M. A. Sekeres, P. Elson, M. E. Kalaycio, A. S. Advani, E. A. Copelan, S. Faderl, H. M. Kantarjian, E. Estey. (2009) Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113:1, 28-36
CrossRef51
Jing Wang, Ping Zhan, Jian Ouyang, Bing Chen, Rongfu Zhou. (2009) Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials. Leukemia & Lymphoma 50:3, 457-459
CrossRef52
Richard Stone. (2008) Timed sequential induction chemotherapy in AML: Time for reflection. American Journal of Hematology 83:11, 829-830
CrossRef53
Matt Kalaycio, Anjali Advani, Brad Pohlman, Mikkael Sekeres, Barbara Tripp, Lisa Rybicki, Ronald Sobecks. (2008) Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. American Journal of Hematology 83:11, 831-834
CrossRef54
Hervé Dombret, Emmanuel Raffoux, Claude Gardin. (2008) Acute Myeloid Leukemia in the Elderly. Seminars in Oncology 35:4, 430-438
CrossRef55
Xavier Thomas. (2008) New emerging applications of molgramostim in acute myeloid leukaemia. Expert Opinion on Drug Metabolism & Toxicology 4:6, 795-806
CrossRef56
Takehiko Mori, Yoshinobu Aisa, Reiko Watanabe, Rie Yamazaki, Jun Kato, Takayuki Shimizu, Naoyuki Shigematsu, Atsushi Kubo, Tomonaru Yajima, Toshifumi Hibi, Yasuo Ikeda, Shinichiro Okamoto. (2008) Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for De Novo Acute Myelogenous Leukemia with a Conditioning Regimen of Total Body Irradiation and Granulocyte Colony-Stimulating Factor-Combined High-Dose Cytarabine. Biology of Blood and Marrow Transplantation 14:6, 651-657
CrossRef57
M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. M. Valk, B. Lowenberg. (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:10, 5078-5085
CrossRef58
Xavier Thomas. (2008) The role of timed sequential chemotherapy in adult acute myelogenous leukemia. Current Hematologic Malignancy Reports 3:2, 89-95
CrossRef59
Stephen D. Nimer. (2008) Is it important to decipher the heterogeneity of “normal karyotype AML”?. Best Practice & Research Clinical Haematology 21:1, 43-52
CrossRef60
Wang-Gang Zhang, Fang-Xia Wang, Yin-Xia Chen, Xin-Mei Cao, Ai-Li He, Jie Liu, Xiao-Rong Ma, Wan-Hong Zhao, Su-Hu Liu, Jian-Li Wang. (2008) Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. American Journal of Hematology 83:3, 185-188
CrossRef61
S. Lugthart, E. van Drunen, Y. van Norden, A. van Hoven, C. A. J. Erpelinck, P. J. M. Valk, H. B. Beverloo, B. Lowenberg, R. Delwel. (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111:8, 4329-4337
CrossRef62
Nobuhiro Kanemura, Hisashi Tsurumi, Senji Kasahara, Takeshi Hara, Toshiki Yamada, Michio Sawada, Naoe Goto, Jun-ichi Kitagawa, Masahito Shimizu, Masami Oyama, Hisataka Moriwaki. (2008) Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematological Oncology 26:1, 33-38
CrossRef63
B. Lowenberg. (2008) Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety. Hematology 2008:1, 1-11
CrossRef64
Si-Xuan Qian, Jian-Yong Li, Tian Tian, Yun-Feng Shen, Yuan-Qiang Jiang, Hua Lu, Han-Xin Wu, Su-Jiang Zhang, Wei Xu. (2007) Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leukemia Research 31:10, 1383-1388
CrossRef65
Dimitri A. Breems, Bob Löwenberg. (2007) Acute Myeloid Leukemia and the Position of Autologous Stem Cell Transplantation. Seminars in Hematology 44:4, 259-266
CrossRef66
M. Heuser, B. Argiropoulos, F. Kuchenbauer, E. Yung, J. Piper, S. Fung, R. F. Schlenk, K. Dohner, T. Hinrichsen, C. Rudolph, A. Schambach, C. Baum, B. Schlegelberger, H. Dohner, A. Ganser, R. K. Humphries. (2007) MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110:5, 1639-1647
CrossRef67
Oliver G. Ottmann, Gesine Bug, Jürgen Krauter. (2007) Current Status of Growth Factors in the Treatment of Acute Myeloid and Lymphoblastic Leukemia. Seminars in Hematology 44:3, 183-192
CrossRef68
Tjakiena Henriette Levenga, Johanna N. H. Timmer-Bonte. (2007) Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies. British Journal of Haematology 138:2, 146-152
CrossRef69
Nicholas B. Heaney, Tessa L. Holyoake. (2007) Therapeutic targets in chronic myeloid leukaemia. Hematological Oncology 25:2, 66-75
CrossRef70
Richard M. Stone. (2007) Novel therapeutic agents in acute myeloid leukemia. Experimental Hematology 35:4, 163-166
CrossRef71
Richard M. Stone. (2007) Targeted agents in AML: much more to do. Best Practice & Research Clinical Haematology 20:1, 39-48
CrossRef72
X Thomas, E Raffoux, S de Botton, C Pautas, P Arnaud, T de Revel, O Reman, C Terré, B Corront, C Gardin, Q-H Le, B Quesnel, C Cordonnier, J-H Bourhis, M Elhamri, P Fenaux, C Preudhomme, M Michallet, S Castaigne, H Dombret. (2007) Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 21:3, 453-461
CrossRef73
Stefania Laurent, Giulio L. Palmisano, Alberto M. Martelli, Tomohiro Kato, Pier Luigi Tazzari, Ivana Pierri, Marino Clavio, Beatrice Dozin, Giuseppe Balbi, Mauro Megna, Anna Morabito, Teresa Lamparelli, Andrea Bacigalupo, Marco Gobbi, Maria Pia Pistillo. (2007) CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. British Journal of Haematology 136:4, 597-608
CrossRef74
T Mori, Y Aisa, A Yokoyama, T Nakazato, R Yamazaki, T Shimizu, A Mihara, J Kato, R Watanabe, N Takayama, Y Ikeda, S Okamoto. (2007) Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplantation 39:4, 217-221
CrossRef75
H. P. Erba. (2007) Prognostic Factors in Elderly Patients with AML and the Implications for Treatment. Hematology 2007:1, 420-428
CrossRef76
Elihu Estey, Hartmut Döhner. (2006) Acute myeloid leukaemia. The Lancet 368:9550, 1894-1907
CrossRef77
, D. W. Milligan, D. Grimwade, J. O. Cullis, L. Bond, D. Swirsky, C. Craddock, J. Kell, J. Homewood, K. Campbell, S. McGinley, K. Wheatley, G. Jackson. (2006) Guidelines on the management of acute myeloid leukaemia in adults. British Journal of Haematology 135:4, 450-474
CrossRef78
Barbara Deschler, Michael Lübbert. (2006) Acute myeloid leukemia: Epidemiology and etiology. Cancer 107:9, 2099-2107
CrossRef79
Jonathan E. Kolitz. (2006) Current therapeutic strategies for acute myeloid leukaemia. British Journal of Haematology 134:6, 555-572
CrossRef80
C. L. Cooper, S. Al-Bedwawi, C. Lee, G. Garber. (2006) Rate of Infectious Complications during Interferon-Based Therapy for Hepatitis C Is Not Related to Neutropenia. Clinical Infectious Diseases 42:12, 1674-1678
CrossRef81
Anjali S. Advani. (2006) Targeting the c-kit receptor in the treatment of acute myelogenous leukemia. Current Hematologic Malignancy Reports 1:2, 101-107
CrossRef82
Jan Styczynski, Mariusz Wysocki. (2006) Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia. British Journal of Haematology 133:4, 397-399
CrossRef83
F Ravandi. (2006) Role of cytokines in the treatment of acute leukemias: a review. Leukemia 20:4, 563-571
CrossRef84
Susan J. J. Swiggers, Marianne A. Kuijpers, Maartje J. M. de Cort, H. Berna Beverloo, J. Mark J. M. Zijlmans. (2006) Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes, Chromosomes and Cancer 45:3, 247-256
CrossRef85
Monika Engelhardt, Yalin Guo, Sebastian Fetscher, Roland Mertelsmann. 2006. Haematopoietic Growth Factors: Therapeutic Uses. .
CrossRef86
Sergio Rutella, Giuseppina Bonanno, Annabella Procoli, Andrea Mariotti, M. Barbara Lucia, Anna Maria Contemi, Roberto Cauda, Luana Fianchi, Giovanni Scambia, Livio Pagano, Giuseppe Leone. (2006) Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Experimental Hematology 34:1, 54-65
CrossRef87
Wolfgang Kern, Claudia Schoch, Torsten Haferlach, Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia. Critical Reviews in Oncology/Hematology 56:2, 283-309
CrossRef88
Michael Heuser, Arnold Ganser. (2005) Colony-stimulating factors in the management of neutropenia and its complications. Annals of Hematology 84:11, 697-708
CrossRef89
Thomas Büchner, Wolfgang E. Berdel, Bernhard Wörmann, Claudia Schoch, Torsten Haferlach, Susanne Schnittger, Wolfgang Kern, Carlo Aul, Eva Lengfelder, Andrea Schumacher, Albrecht Reichle, Peter Staib, Leopold Balleisen, Hartmut Eimermacher, Andreas Grüneisen, Herbert Rasche, Maria Cristina Sauerland, Achim Heinecke, Rolf M. Mesters, Hubert L. Serve, Joachim Kienast, Wolfgang Hiddemann. (2005) Treatment of older patients with AML. Critical Reviews in Oncology/Hematology 56:2, 247-259
CrossRef90
Wolfgang Kern, Susanne Schnittger. (2005) Monitoring of minimal residual disease in acute myeloid leukemia Monitorisierung minimaler Resterkrankung bei akuter myeloischer Leukämie. LaboratoriumsMedizin 29:5, 343-367
CrossRef91
Heather G. Jørgensen, Elaine K. Allan, Joanne C. Mountford, Linda Richmond, Simon Harrison, Moira A. Elliott, Tessa L. Holyoake. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology 33:10, 1140-1146
CrossRef92
Dimitri A. Breems, Bob Lowenberg. (2005) Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. British Journal of Haematology 130:6, 825-833
CrossRef93
Thomas Buechner, Wolfgang Berdel, Claudia Schoch, Torsten Haferlach, Hubert Serve, Susanne Schnittger, Wolfgang Kern, Joelle Tchinda, Albrecht Reichle, Peter Staib, Wolf-Dieter Ludwig, Carlo Aul, Maria-Cristina Sauerland, Achim Heinecke, Bernhard Woermann, Wolfgang Hiddemann for the German A Group. (2005) Treatment of AML in biological subgroups. Hematology 10:4, 281-285
CrossRef94
E Mc Cormack, Ø Bruserud, B T Gjertsen. (2005) Animal models of acute myelogenous leukaemia – development, application and future perspectives. Leukemia 19:5, 687-706
CrossRef95
Dimitri A. Breems, Marc A. Boogaerts, Adriaan W. Dekker, Wim L. J. Van Putten, Pieter Sonneveld, Peter C. Huijgens, Johannes Van der Lelie, Edo Vellenga, Alois Gratwohl, Gregor E. G. Verhoef, Leo F. Verdonck, Bob Löwenberg. (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. British Journal of Haematology 128:1, 59-65
CrossRef96
AP Grigg, J Reynolds, A McQuillan, SK Juneja, J Di Iulio, C Hui, C Smith, R Kimber, KF Bradstock, on behalf of the Australasian Leuka. (2005) Prognostic features for response and survival in elderly patients with <emph type="3">de novo</emph> acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia & Lymphoma 46:3, 367-375
CrossRef97
Georgine E. de Greef, Wim L. J. van Putten, Marc Boogaerts, Peter C. Huijgens, Leo F. Verdonck, Edo Vellenga, Matthias Theobald, Emanuel Jacky, Bob Lowenberg, , . (2005) Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. British Journal of Haematology 128:2, 184-191
CrossRef98
Heather G. J
rgensen, Mhairi Copland, Tessa L. Holyoake. (2005) Granulocyte?colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103:1, 210-210
CrossRef99
Rami S Komrokji, Gary H Lyman. (2004) The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapy 4:12, 1897-1910
CrossRef100
Wolf-K Hofmann, Claudia Baldus, Lutz Uharek, Eckhard Thiel. (2004) Therapeutic spectrum in the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy 5:12, 2451-2458
CrossRef101
Jeffrey E. Rubnitz, Shelly Lensing, Yinmei Zhou, John T. Sandlund, Bassem I. Razzouk, Raul C. Ribeiro, Ching-Hon Pui. (2004) Death during induction therapy and first remission of acute leukemia in childhood. Cancer 101:7, 1677-1684
CrossRef102
Alfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Mary B. Rios, Moshe Talpaz, Jorge Cortes. (2004) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100:12, 2592-2597
CrossRef103
Büchner, Thomas, Berdel, Wolfgang E., , Hiddemann, Wolfgang, . (2004) Priming with Granulocyte Colony-Stimulating Factor — Relation to High-Dose Cytarabine in Acute Myeloid Leukemia. New England Journal of Medicine 350:21, 2215-2216
Full Text104
Michael Witcher, Wilson H Miller. (2004) Cytokines and retinoic acid therapy for APL: new tricks from an old combination. Leukemia Research 28:5, 447-448
CrossRef105
Valk, Peter J.M., Verhaak, Roel G.W., Beijen, M. AntoinetteErpelinck, Claudia A.J.van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk, Boer, Judith M., Beverloo, H. Berna, Moorhouse, Michael J., van der Spek, Peter J., Löwenberg, Bob, Delwel, Ruud, . (2004) Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. New England Journal of Medicine 350:16, 1617-1628
Full Text106
Tsuyoshi Nakamaki, Hiroshi Kawabata, Bungo Saito, Manabu Matsunawa, Junko Suzuki, Daisuke Adachi, Shigeru Tomoyasu, H. Phillip Koeffler. (2004) Elevated levels of transferrin receptor 2 mRNA, not transferrin receptor 1 mRNA, are associated with increased survival in acute myeloid leukaemia. British Journal of Haematology 125:1, 42-49
CrossRef107
R Hayward. (2003) Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research. Surgical Oncology 12:4, 289-304
CrossRef108
(2003) G-CSF Priming in Acute Myelogenous Leukemia. New England Journal of Medicine 349:21, 2071-2072
Full Text109
Schiffer, Charles A., . (2003) Hematopoietic Growth Factors and the Future of Therapeutic Research on Acute Myeloid Leukemia. New England Journal of Medicine 349:8, 727-729
Full Text
- Letters
